中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
25期
78-80,90
,共4页
康复新液%辅助治疗%颈淋巴结核%临床效果
康複新液%輔助治療%頸淋巴結覈%臨床效果
강복신액%보조치료%경림파결핵%림상효과
Kangfuxin Solution%Adjuvant therapy%Cervical tuberculous lymphadenitis%Clinical effect
目的：观察康复新液对颈淋巴结核的辅助治疗效果。方法将2012年6月~2013年6月江苏省无锡市第五人民医院收治的100例颈淋巴结核患者按随机数字表法分为对照组和治疗组，每组50例。对照组常规应用利福平、异烟肼、吡嗪酰胺、乙胺丁醇进行抗结核治疗，治疗组在对照组的基础上加用康复新液。比较不同时间两组患者的症状缓解率、淋巴结吸收率、术后复发率和不良反应及并发症情况。结果治疗组1个月、3个月和6个月临床症状缓解率为90%、98%和100%，较对照组的58%、68%和86%显著升高，差异有高度统计学意义(P<0.01)。治疗组1个月、3个月和6个月的淋巴结吸收率分别为64%、86%和94%，高于对照组的32%、60%和84%，差异有统计学意义(P<0.05)。与对照组比较，治疗组患者术后复发率和不良反应及并发症的发生率均降低，差异有统计学意义(P<0.05)。结论康复新液联合常规抗结核药可提高颈部淋巴结核的症状缓解率和淋巴结吸收率，降低复发率和不良反应及并发症的发生率，值得临床推广使用。
目的：觀察康複新液對頸淋巴結覈的輔助治療效果。方法將2012年6月~2013年6月江囌省無錫市第五人民醫院收治的100例頸淋巴結覈患者按隨機數字錶法分為對照組和治療組，每組50例。對照組常規應用利福平、異煙肼、吡嗪酰胺、乙胺丁醇進行抗結覈治療，治療組在對照組的基礎上加用康複新液。比較不同時間兩組患者的癥狀緩解率、淋巴結吸收率、術後複髮率和不良反應及併髮癥情況。結果治療組1箇月、3箇月和6箇月臨床癥狀緩解率為90%、98%和100%，較對照組的58%、68%和86%顯著升高，差異有高度統計學意義(P<0.01)。治療組1箇月、3箇月和6箇月的淋巴結吸收率分彆為64%、86%和94%，高于對照組的32%、60%和84%，差異有統計學意義(P<0.05)。與對照組比較，治療組患者術後複髮率和不良反應及併髮癥的髮生率均降低，差異有統計學意義(P<0.05)。結論康複新液聯閤常規抗結覈藥可提高頸部淋巴結覈的癥狀緩解率和淋巴結吸收率，降低複髮率和不良反應及併髮癥的髮生率，值得臨床推廣使用。
목적：관찰강복신액대경림파결핵적보조치료효과。방법장2012년6월~2013년6월강소성무석시제오인민의원수치적100례경림파결핵환자안수궤수자표법분위대조조화치료조，매조50례。대조조상규응용리복평、이연정、필진선알、을알정순진행항결핵치료，치료조재대조조적기출상가용강복신액。비교불동시간량조환자적증상완해솔、림파결흡수솔、술후복발솔화불량반응급병발증정황。결과치료조1개월、3개월화6개월림상증상완해솔위90%、98%화100%，교대조조적58%、68%화86%현저승고，차이유고도통계학의의(P<0.01)。치료조1개월、3개월화6개월적림파결흡수솔분별위64%、86%화94%，고우대조조적32%、60%화84%，차이유통계학의의(P<0.05)。여대조조비교，치료조환자술후복발솔화불량반응급병발증적발생솔균강저，차이유통계학의의(P<0.05)。결론강복신액연합상규항결핵약가제고경부림파결핵적증상완해솔화림파결흡수솔，강저복발솔화불량반응급병발증적발생솔，치득림상추엄사용。
Objective To observe clinical effect of Kangfuxin Solution (KFXS) adjuvant treating cervical tuberculosis lym-phadenitis (CTL). Methods 100 CTL patients who were treated in the 5th People's Hospital of Wuxi City from June 2012 to June 2013 were divided into control group and treatment group by digital random method, with 50 cases in each group. Control group was treated with routine application of anti-tuberculosis treatment with Rifampin, Isoniazid, Pyrazinamide and Ethambutol. Treatment group used KFXS on the basis of the control group. Lymph nodes symptom remission rate, absorption rate, postoperative recurrence rate and adverse reactions and complications incidence were compared. Results Clinical symptom relief rate in treatment group after treated for 1 month, 3 months and 6 months were 90%, 98% and 100% respectively, which were significantly higher than 58%, 68% and 86% in the control group. The differences were statistically significant (P< 0.01). Lymph node absorption rate in treatment group after treated for 1 month, 3 months and 6 months were 64%, 86% and 94% respectively, which were higher than 32%, 60% and 84%in control group, the differences were statistically significant (P< 0.05). Compared with control group, postoperative re-currence rate and the incidence of adverse reactions and complications in treatment group were reduced, the differences were statistically significant (P< 0.05). Conclusion KFXS combined routine anti-tuberculosis medicine can improve the neck lymph nodes lymphoid tuberculosis symptom remission rate and absorption rate, reduce the recurrence rate and incidence of adverse reactions and complications, which is worthy of clinical wide usage.
